Results on SARS-CoV-2 mRNA Vaccine Booster from an Open-Label Multicenter Study in Ofatumumab-Treated Participants with Relapsing Multiple Sclerosis.
Tjalf ZiemssenEugen SchlegelMarie GrothBenjamin EttleTobias BoppPublished in: Vaccines (2023)
Booster vaccinations increase neutralizing antibody titers in ofatumumab-treated patients. A booster is recommended in ofatumumab-treated patients.